Hikma launches Norepinephrine Bitartrate Injection, USP


Hikma launches Norepinephrine Bitartrate Injection, USP

London, 22 March 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable), the multinational pharmaceutical company, has launched Norepinephrine Bitartrate Injection, USP, 4mg/4mL in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc.

Hikma’s Norepinephrine Bitartrate Injection, USP is indicated for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions) and as an adjunct in the treatment of cardiac arrest and profound hypotension.

According to IQVIA, US sales of Norepinephrine Bitartrate Injection were approximately $97 million in the 12 months ending January 2019.

Riad Mechlaoui, President of Injectables said, “The launch of Norepinephrine Bitartrate Injection in the US is the latest example of how Hikma is continuing to expand its comprehensive portfolio of quality injectable medicines available to US hospitals. We are committed to providing quality medicines to doctors and their patients and intend to continue identifying and launching injectable medicines that meet the growing needs of US hospitals and clinics.”

Hikma is the third largest US supplier of generic injectable medicines with a growing portfolio of around 100 products.  Today, one in every six injectable medicines used in US hospitals is a Hikma product.